The European Patent Office (EPO) has published patent application EP4333983A1, titled "MESOTHELIN ISOFORM BINDING MOLECULES AND CHIMERIC PD1 RECEPTOR MOLECULES, CELLS CONTAINING THE SAME AND USES THEREOF." The application was filed by Immunocell Therapeutics, Inc. and includes detailed IPC classifications related to therapeutic compositions and antibodies.

This publication represents a new patent filing and does not impose immediate compliance obligations on regulated entities. It is primarily of interest to legal and R&D departments involved in intellectual property and pharmaceutical development within the designated European states. Compliance officers should note this as a development in the patent landscape for novel therapeutic molecules.